(J Am Heart Assoc. 2018;7:e010735 DOI: 10.1161/JAHA.118.010735.)30571488

Clinical PerspectiveWhat Is New?Abnormal blood pressure (BP) response to exercise testing was found in more than half of patients with moderate or severe aortic stenosis.In particular exaggerated BP response was identified as a potential harmful response, and was strongly related to higher resting BP, left ventricular mass, and increased arterial stiffness independent of hypertension.What Are the Clinical Implications?An exaggerated BP response to exercise testing in aortic stenosis patients may identify patients with poorly controlled hypertension.These patients may benefit from strict BP control to reduce vascular load and subsequent risk of cardiovascular complications.

Introduction {#jah33648-sec-0008}
============

Exercise treadmill testing (ETT) provides clinically important diagnostic and prognostic information in different patient populations. In patients with asymptomatic moderate or severe aortic stenosis (AS), this includes both symptoms and heart rate and blood pressure (BP) responses to exercise.[1](#jah33648-bib-0001){ref-type="ref"}, [2](#jah33648-bib-0002){ref-type="ref"} Symptoms revealed by ETT are a class I indication for surgery while a fall in systolic BP is a class IIa indication.[1](#jah33648-bib-0001){ref-type="ref"}, [2](#jah33648-bib-0002){ref-type="ref"} However some asymptomatic patients may exhibit an exaggerated BP response (EBPR) to exercise, irrespective of the BP values at rest or of a history of hypertension. In the general population this phenomenon is associated with a greater risk of incident hypertension[3](#jah33648-bib-0003){ref-type="ref"}, [4](#jah33648-bib-0004){ref-type="ref"}, [5](#jah33648-bib-0005){ref-type="ref"} as well as of cardiovascular morbidity and mortality.[4](#jah33648-bib-0004){ref-type="ref"}, [6](#jah33648-bib-0006){ref-type="ref"}, [7](#jah33648-bib-0007){ref-type="ref"} Although arterial hypertension is the most common comorbidity in patients with AS,[8](#jah33648-bib-0008){ref-type="ref"}, [9](#jah33648-bib-0009){ref-type="ref"}, [10](#jah33648-bib-0010){ref-type="ref"} the significance of EBPR in AS is not known. The aim of the present study was to assess the clinical implications and prognostic value of EBPR in moderate or severe AS using data from the EXTAS (Exercise Testing in AS) cohort study.

Methods {#jah33648-sec-0009}
=======

Data Availability {#jah33648-sec-0010}
-----------------

The data, analytic methods, and study materials will not be made freely available to other researchers for purposes of reproducing the results or replicating the procedure since the complete study data set contains potentially identifying data.

Patient Population {#jah33648-sec-0011}
------------------

The EXTAS study is a retrospective analysis of data gathered prospectively between January 2000 and May 2017. A total of 651 patients aged \>18 years with moderate (effective orifice area 1.0--1.5 cm^2^) or severe (effective orifice area \<1.0 cm^2^) AS[1](#jah33648-bib-0001){ref-type="ref"}, [2](#jah33648-bib-0002){ref-type="ref"} were assessed in a dedicated heart valve clinic at Guy\'s and St Thomas' Hospital. During a median follow‐up of 25 months (mean 34.9±34.6 months) only 7 patients were lost to follow‐up. All patients underwent ETT at presentation and most were restudied when their AS crossed the threshold between moderate and severe, and thereafter annually. The present analysis focuses on the baseline data including ETT, echocardiography, and clinical characteristics. Patients were excluded from the study if they declared spontaneous symptoms justifying surgery (n=283), had co‐existent additional valve disease of more than moderate severity (12 patients with severe mitral regurgitation, 4 with severe mitral stenosis, and 5 with severe aortic regurgitation) or had an inability to exercise owing to comorbidities such as peripheral vascular disease (n=2), chronic obstructive pulmonary disease (n=24), anemia (n=2), or immobility or severe arthritis (n=3). The remaining 316 patients (49%) were apparently asymptomatic by history and eligible for ETT. Of these, peak systolic BP was not recorded in 15 patients, leaving 301 patients eligible for inclusion in the present analysis. Hypercholesterolemia was defined as treatment with lipid‐lowering drugs. Resting clinic BP before ETT was measured with a semiautomatic device with the patient resting for 5 to 10 minutes in the sitting position. Hypertension was defined from a history of elevated BP values, past or current treatment with antihypertensive agents or a BP at the baseline clinic visit \>140/90 mm Hg.[8](#jah33648-bib-0008){ref-type="ref"} Before surgical or transcutaneous aortic valve replacement (AVR), all patients underwent conventional coronary angiography. Coronary artery disease was defined as previous myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention, or angiographic evidence of coronary artery disease (\>70% stenosis of ≥1 main epicardial arteries). The study was approved by the local Institutional Review Board (Study Protocol no. 7461/2017), and the requirement about the informed consent was waived. The study was managed and conducted in accordance with the Declaration of Helsinki, and latest Good Clinical Practice guidelines.

Exercise Treadmill Test Protocol {#jah33648-sec-0012}
--------------------------------

The method for ETT have previously been described in detail.[8](#jah33648-bib-0008){ref-type="ref"} Briefly, ETTs were performed according to American College of Cardiology/American Heart Association practice guidelines using a Bruce protocol modified by 2 warm‐up stages.[11](#jah33648-bib-0011){ref-type="ref"}, [12](#jah33648-bib-0012){ref-type="ref"} The test was stopped prematurely for symptoms (significant breathlessness or any chest constriction or dizziness), progressive ventricular ectopy \>3 beats, new atrial fibrillation, a sustained fall in systolic BP \>20 mm Hg from the previous stage or \>5 mm ST‐segment depression. The following measures were recorded: exercise time, exercise capacity in metabolic equivalents (METs), maximum rise in systolic BP and maximum fall from peak, ST‐segment depression in millimeters. METs were calculated from the speed and gradient of the treadmill by the machine\'s software using the formula (METS=\[(speed×0.1)+(gradient/100×1.8×speed)+3.5\]/3.5), where speed is measured in m/s and gradient as a percentage. One MET is usually defined as the energy expended at rest which is equal to a body oxygen consumption of nearly 3.5 mL per kilogram of body weight for an average adult.[13](#jah33648-bib-0013){ref-type="ref"} Blunted BP response was defined as a sustained fall in systolic BP ≥20 mm Hg below the previous stage or a failure to rise from the baseline level.[14](#jah33648-bib-0014){ref-type="ref"} An EBPR was defined as a peak systolic BP ≥190 mm Hg during ETT. Abnormal BP response was defined as either blunted BP response or EBPR.

Transthoracic Echocardiography {#jah33648-sec-0013}
------------------------------

Echocardiographic data were obtained using commercially available ultrasound systems (Vingmed system 5, 7, 9 GE Medical, Milwaukee, Wisconsin, USA and a Philips "Epiq 7" cardiac ultrasound machine). The severity of AS, left ventricular (LV) wall thicknesses, chamber dimensions, stroke volume and ejection fraction were measured according to the prevalent European and United States guidelines of the time.[15](#jah33648-bib-0015){ref-type="ref"} The recommended methodology did not change over the period of the study. Although the thresholds for moderate and severe AS changed in 2009,[15](#jah33648-bib-0015){ref-type="ref"} these were standardized as part of our retrospective analysis. Mean transaortic resistance was calculated as 1.333×(mean transaortic pressure difference/mean transaortic flow) in dyne s/cm^5^.[16](#jah33648-bib-0016){ref-type="ref"} LV hypertrophy was diagnosed according to the prognostically validated cutoff values of LV mass \>46.7 g/m^2.7^ in women and 49.2 g/m^2.7^ in men, respectively, and relative wall thickness as LV posterior wall thickness/LV internal radius at end‐diastole, and considered increased if ≥0.43.[17](#jah33648-bib-0017){ref-type="ref"} Systemic arterial distensibility was derived from the ratio of stroke volume index (SVi) divided by central pulse pressure (PP) (SV/PP) (mL/m^2^ per mm Hg), where central PP was calculated from brachial PP: central PP=(brachial PP×0.49)+(age×0.30)+7.11.[9](#jah33648-bib-0009){ref-type="ref"}, [18](#jah33648-bib-0018){ref-type="ref"} A low systemic arterial distensibility was defined as SVi/PP ≤0.6 mL/m^2^ per mm Hg. The ratio of PP to SVi (PP/SVi) was used as an indirect measure of systemic arterial stiffness.[19](#jah33648-bib-0019){ref-type="ref"}

Study End Points {#jah33648-sec-0014}
----------------

All‐cause mortality and AVR (either surgical or via a transcatheter approach) were recorded during follow‐up. Deaths were confirmed by reviewing the electronic patient record or a death certificate with September 19, 2017 as the censoring date. Follow‐up time was calculated from the baseline ETT until AVR, death or censoring.

Statistical Analyses {#jah33648-sec-0015}
--------------------

SPSS version 24.0 (IBM Corporation, Armonk, NY) was used for data management and statistical analyses. Continuous variables were tested for normality of distribution and presented as mean±SD. Comparison between the 3 groups was done by analysis of variance with Scheffe\'s post‐hoc test for continuous variables and a general linear model with Sidak\'s post‐hoc test for categorical variables. The predictors of EBPR were first identified in univariable binary logistic regression models, reported as odds ratio and 95% confidence interval (CI). Then based on univariate associations of a *P*\<0.10, predictors of EBPR were selected and included in the multivariate logistic regression model. The bivariate association between peak systolic blood pressure and pretest systolic blood pressure was assessed with Pearson\'s correlation coefficient. Kaplan--Meier curves were used to examine cumulative event rates, and the difference between groups was tested using a log‐rank test. Cox proportional Hazard models were used to assess the association between EBPR and outcomes. Non‐linear associations between pre‐ETT systolic BP, peak systolic BP during ETT, difference between pre‐ETT systolic BP and peak systolic BP, and ratio of peak‐by pre‐ETT systolic BP and all‐cause mortality were explored by fitting the Cox proportional hazard model with penalized smoothing splines. A *P*\<0.05 was considered to be statistically significant.

Results {#jah33648-sec-0016}
=======

Baseline Characteristics and Patterns of Blood Pressure Responses During Exercise {#jah33648-sec-0017}
---------------------------------------------------------------------------------

The mean age of the 301 patients was 65±12 years, and 67% were men. At baseline the AS was moderate in 200 (66%) and severe in 101 (34%). Two‐hundred eighty‐two (94%) were in sinus rhythm, 13 (4%) in atrial fibrillation and 6 (2%) were paced. An abnormal BP response during the baseline ETT was found in 174 (58%) patients. Of these, 64 (37%) exhibited an EBPR and 110 (63%) a blunted BP response. There was no difference in the rates of abnormal BP responses between those patients with moderate and severe AS (\[EBPR: 21% versus 22%, *P*=0.876\] and \[blunted BP response: 35% versus 40%, *P*=0.647\]). Patients with EBPR were more likely to be older or have documented hypertension, as well as higher clinic systolic BP, LV ejection fraction and LV mass (all *P*\<0.05) (Table [1](#jah33648-tbl-0001){ref-type="table"}). On average, clinic systolic BP was 21 mm Hg higher in patients with EBPR compared with those with a normal BP response to ETT. PP/SVi, an indirect measure of systemic arterial stiffness, was also significantly higher in patients with EBPR compared with those with a normal BP response to ETT (Table [1](#jah33648-tbl-0001){ref-type="table"}). A low‐systemic arterial distensibility (SVi/PP ≤0.6 mL/m^2^ per mm Hg) was observed in 21% (n=63) of the entire study population, the prevalence being nearly 3‐fold as high in patients with EBPR compared with those with normal BP response to ETT (Table [1](#jah33648-tbl-0001){ref-type="table"}). A Pearson test for bivariate correlation showed that resting pretest systolic BP correlated closely with peak systolic BP during the ETT and was significantly higher in patients with EBPR compared with those with a normal BP response to ETT (Figure [1](#jah33648-fig-0001){ref-type="fig"}, Table [1](#jah33648-tbl-0001){ref-type="table"}). The average peak systolic BP was 202±10 in patients with EPBR versus 165±17 mm Hg in those with a normal BP response (Table [1](#jah33648-tbl-0001){ref-type="table"}). Furthermore, a statistically significant correlation was found between LV mass index and peak systolic BP during the ETT (*r*=0.22, *P*=0.018), but not with pretest systolic BP (*r*=0.13, *P*=0.064). In the entire study population, the prevalence of abnormal LV geometry was 82%, most commonly concentric LV hypertrophy (Figure [2](#jah33648-fig-0002){ref-type="fig"}). There was no difference in exercise duration, metabolic equivalents or severity of AS between patients with a normal BP response and EBPR (all *P*=NS), but patients with a blunted BP response had a significantly lower performance on ETT compared with patients with a normal BP response (*P*\<0.01) (Table [1](#jah33648-tbl-0001){ref-type="table"}).

###### 

Characteristics of the Study Population According to BP Response During Exercise Treadmill Test

                                              Normal BP Response (n=127)   Blunted BP Response (n=110)                         Exaggerated BP Response (n=64)                                                               *P* Value
  ------------------------------------------- ---------------------------- --------------------------------------------------- -------------------------------------------------------------------------------------------- -----------
  Demographic and clinical data                                                                                                                                                                                             
  Age, y                                      63±12                        67±13[\*](#jah33648-note-0002){ref-type="fn"}       68±10[\*](#jah33648-note-0002){ref-type="fn"}                                                0.004
  Men/women                                   63/37                        68/32                                               70/30                                                                                        0.533
  Body mass index, kg/m^2^                    28.9±13.7                    27.5±4.5                                            28.2±4.7                                                                                     0.601
  Current and ex‐smokers, n (%)               64 (50.5)                    45 (41)                                             35 (54)                                                                                      0.239
  Clinic systolic BP, mm Hg                   135±16                       142±18[\*](#jah33648-note-0002){ref-type="fn"}      156±19[\*](#jah33648-note-0002){ref-type="fn"} ^,^ [†](#jah33648-note-0003){ref-type="fn"}   \<0.001
  Clinic diastolic BP, mm Hg                  82±12                        82±12                                               83±15                                                                                        0.712
  Hypertension, n (%)                         77 (61)                      85 (77)                                             54 (84)                                                                                      0.001
  Antihypertensive treatment, n (%)           69 (55)                      77 (70)                                             47 (73)                                                                                      0.039
  Coronary artery disease, n (%)              58 (46)                      52 (47)                                             38 (59)                                                                                      0.289
  Diabetes mellitus, n (%)                    15 (12)                      19 (17)                                             8 (12)                                                                                       0.535
  Hypercholesterolemia, n (%)                 81 (64)                      70 (64)                                             47 (73)                                                                                      0.468
  Echocardiographic data                                                                                                                                                                                                    
  Left atrium dimension, cm                   3.7±0.6                      3.8±0.8                                             3.9±0.6                                                                                      0.298
  Aortic root diameter, cm                    3.3±0.5                      3.3±0.5                                             3.3±0.5                                                                                      0.859
  Aortic annulus diameter, cm                 2.1±0.2                      2.1±0.3                                             2.0±0.2                                                                                      0.124
  LV end‐diastolic diameter, cm               4.4±0.6                      4.6±0.7                                             4.6±0.7                                                                                      0.197
  Interventricular septal thickness, cm       1.3±0.3                      1.3±0.3                                             1.4±0.3                                                                                      0.157
  LV mass index, g/m^2.7^                     48.2±14.9                    51.3±18.1                                           58.7±19.1[\*](#jah33648-note-0002){ref-type="fn"}                                            0.007
  LV hypertrophy, n (%)                       61 (48)                      56 (51)                                             44 (68)                                                                                      0.027
  LV ejection fraction, %                     61±6                         59±8                                                62±6[‡](#jah33648-note-0003){ref-type="fn"}                                                  0.013
  Mean transaortic resistance, dyne s/cm^5^   198±80                       185±78                                              195±98                                                                                       0.872
  Mean aortic gradient, mm Hg                 34±14                        35±13                                               34±12                                                                                        0.897
  Effective orifice area, cm^2^               0.95±0.22                    0.91±0.22                                           0.95±0.22                                                                                    0.281
  Doppler stroke volume index, mL/m^2^        43±14                        42±14                                               45±10                                                                                        0.533
  PP/SVi, mm Hg/mL per m^2^                   1.27±0.48                    1.55±0.52[\*](#jah33648-note-0002){ref-type="fn"}   1.71±0.68[\*](#jah33648-note-0002){ref-type="fn"}                                            \<0.001
  SVi/PP, mL/m^2^ per mm Hg                   0.85±0.28                    0.75±0.27                                           0.73±0.22                                                                                    0.023
  SVi/PP ≤0.6 mL/m^2^ per mm Hg, n (%)        12 (10)                      34 (31)                                             18 (29)                                                                                      0.002
  Exercise treadmill testing data                                                                                                                                                                                           
  Systolic BP before exercise, mm Hg          133±15                       144±19                                              153±18[\*](#jah33648-note-0002){ref-type="fn"} ^,^ [†](#jah33648-note-0003){ref-type="fn"}   \<0.001
  Diastolic BP beforeexercise, mm Hg          84±10                        85±11                                               87±12                                                                                        0.275
  Target heart rate achieved, %               87±14                        84±17                                               89±11[‡](#jah33648-note-0003){ref-type="fn"}                                                 0.026
  Peak systolic BP, mm Hg                     165±17                       147±20[\*](#jah33648-note-0002){ref-type="fn"}      202±10[\*](#jah33648-note-0002){ref-type="fn"} ^,^ [†](#jah33648-note-0003){ref-type="fn"}   \<0.001
  Peak diastolic BP, mm Hg                    90±15                        86±15                                               100±16[\*](#jah33648-note-0002){ref-type="fn"} ^,^ [†](#jah33648-note-0003){ref-type="fn"}   \<0.001
  Peak heart rate, beat/min                   137±26                       128±26[\*](#jah33648-note-0002){ref-type="fn"}      137±19                                                                                       0.010
  Exercise duration, min                      10.5±4.5                     8.9±4.4                                             9.9±3.9                                                                                      0.014
  Metabolic equivalents (METs)                9.3±4.5                      8.0±4.6                                             8.7±4.4                                                                                      0.064

BP indicates blood pressure; LV, left ventricular; PP/SVi, pulse pressure/stroke volume index.

\**P*\<0.01 vs normal BP response.

^†^ *P*\<0.01, ^‡^ *P*\<0.05 vs blunted BP response.

![Scatterplot of peak systolic blood pressure during ETT and pre ETT systolic blood pressure. ETT indicates exercise treadmill test.](JAH3-7-e010735-g001){#jah33648-fig-0001}

![The prevalence of the types of left ventricular geometry according to BP response during exercise treadmill test. BP indicates blood pressure; LV, left ventricular; LVH, left ventricular hypertrophy.](JAH3-7-e010735-g002){#jah33648-fig-0002}

Predictors of Exaggerated Blood Pressure Response {#jah33648-sec-0018}
-------------------------------------------------

In a univariate logistic regression analysis, higher age, the presence of hypertension, abnormal LV geometry, higher systolic BP, LV mass, and higher ejection fraction and PP/SVi, but lower systemic arterial distensibility were all associated with the presence of EBPR (Table [2](#jah33648-tbl-0002){ref-type="table"}). In a multivariate logistic regression analysis, EBPR was associated with higher PP/SVi and LV mass independent of age, hypertension, aortic annulus and left atrium diameter, and LV ejection fraction (Table [2](#jah33648-tbl-0002){ref-type="table"}). In the same multivariate model, when hypertension was replaced by clinic systolic BP, EBPR retained a significant association with higher systolic BP (odds ratio per 1 SD systolic BP 2.08, 95% CI 1.08--4.02, *P*=0.030) and higher LV mass (odds ratio per 1 SD LV mass 1.81, 95% CI 1.11--2.97, *P*=0.019) independent of age, aortic annulus and left atrium diameter, and LV ejection fraction.

###### 

Predictors of Exaggerated Blood Pressure Response in Univariate and Multivariate Logistic Regression Analyses in Moderate or Severe Aortic Stenosis

                                                  Univariate            Multivariate                        
  ----------------------------------------------- --------------------- -------------- -------------------- -------
  Age, y                                          1.02 (0.99--1.05)     0.065          1.05 (1.00--1.10)    0.046
  Male sex                                        1.25 (0.67--2.28)     0.461                               
  Weight, kg                                      1.01 (0.99--1.03)     0.415                               
  Body mass index, kg/m^2^                        0.99 (0.96--1.03)     0.838                               
  Clinic SBP (per 1SD \[7.5 mm Hg\] increase)     2.93 (2.03--4.21)     \<0.001                             
  Clinic DBP, mm Hg                               1.00 (0.98--1.03)     0.703                               
  Pre‐test SBP (per 1SD \[7.4 mm Hg\] increase)   2.39 (1.71--3.34)     \<0.001                             
  Pre‐test DBP (per 1SD \[7.7 mm Hg\] increase)   1.20 (0.90--1.58)     0.216                               
  Hypertension                                    2.48 (1.20--5.14)     0.014          1.57 (0.50--4.88)    0.437
  Antihypertensive treatment                      1.64 (0.79--3.41)     0.189                               
  Diabetes mellitus                               0.83 (0.34--2.01)     0.65                                
  Hypercholesterolemia                            2.43 (0.86--6.87)     0.093                               
  Aortic annulus diameter, mm                     0.22 (0.05--0.94)     0.040          1.14 (0.10--13.40)   0.917
  LV ejection fraction (%)                        1.05 (1.00--1.10)     0.045          1.05 (0.97--1.14)    0.206
  Left atrium diameter, cm                        1.04 (0.99--1.09)     0.088          0.96 (0.89--1.04)    0.303
  Interventricular septal thickness, cm           2.80 (0.94--8.33)     0.064                               
  Posterior wall thickness, cm                    5.80 (1.50--22.42)    0.011                               
  LV mass (per 1 SD \[2.8 g\] increase)           1.43 (1.07--1.91)     0.015          2.04 (1.23--3.38)    0.012
  High LV mass, g/m^2.7^                          2.19 (1.04--4.64)     0.040                               
  LV hypertrophy                                  2.19 (1.04--4.64)     0.039                               
  Abnormal LV geometry                            10.23 (1.35--77.27)   0.024                               
  Effective orifice area, cm^2^                   1.65 (0.46--5.87)     0.441                               
  Doppler stroke volume, mL/m^2^                  1.00 (0.99--1.02)     0.586                               
  PP/SVi, mm Hg/mL per m^2^                       2.58 (1.63--4.88)     0.004          2.47 (1.02--6.00)    0.037
  Low SAD (SVi/PP ≤0.6 mL/m^2^ per mm Hg)         2.48 (1.15--5.33)     0.020                               

CI indicates confidence interval; DBP, diastolic blood pressure; HbA~1c~, hemoglobin A~1c~; LV, left ventricular; OR, odds ratio; PWV, pulse wave velocity; SAD; systemic arterial distensibility; SBP, systolic blood pressure.

Prediction of Outcomes by ETT Measures {#jah33648-sec-0019}
--------------------------------------

During a mean follow up period of 34.9±34.6 months 250 (84%) patients had events, 222 AVR and 28 deaths. AVR occurred in 79% (n=100) with a normal BP response, 71% (n=78) with a blunted BP response, and 72% (n=46) with EBPR, (*P*=0.339). Death occurred in 7 (6%) with a normal BP response, 16 (15%) with a blunted BP response, and 5 (8%) with EBPR (*P*=0.051). In a univariate Cox regression analysis, the presence of EBPR was neither associated with all‐cause mortality (hazard ratio \[HR\] 0.93, 95% CI 0.35--2.45, *P*=0.884) nor AVR (HR 1.04, 95% CI 0.75--1.43, *P*=0.838). However a Kaplan--Meier analysis by BP response, showed a trend towards a difference in survival between the groups (Log‐rank *P*=0.061) (Figure [3](#jah33648-fig-0003){ref-type="fig"}). Blunted BP response was associated with all‐cause mortality (HR 2.30, 95% CI 1.09--4.88, *P*=0.029) in univariate Cox regression analysis, but when adjusting for age, male sex, mean pressure gradient and hypertension, the association between blunted BP response and all‐cause mortality did not remain significant (HR 1.80, 95% CI 0.75--4.28, *P*=0.186).

![Kaplan--Meier plot illustrating the impact of exaggerated BP response on cumulative survival free from total mortality. BP indicates blood pressure.](JAH3-7-e010735-g003){#jah33648-fig-0003}

In the unadjusted Cox proportional models, the difference between pretest systolic BP and peak systolic BP showed an inverse correlation with all‐cause mortality (Figure [4](#jah33648-fig-0004){ref-type="fig"}A). Mortality was highest if the BP rose by less than 20 mm Hg which applies patients with blunted BP response (Figure [4](#jah33648-fig-0004){ref-type="fig"}A). Peak systolic BP during ETT had no significant association with all‐cause mortality (Figure [4](#jah33648-fig-0004){ref-type="fig"}B) whilst pre‐ETT systolic BP showed a positive correlation, and the ratio of peak by pretest systolic BP an inverse correlation, with all‐cause mortality (Figure [4](#jah33648-fig-0004){ref-type="fig"}C and [4](#jah33648-fig-0004){ref-type="fig"}D). When patients with a blunted BP response were excluded from the survival analyses, comparing only EBPR versus normal BP response, the results did not change (all‐cause mortality: HR 1.70, 95% CI 0.54--5.36, *P*=0.368 and AVR: HR 1.01, 95% CI 0.70--1.44, *P*=0.973).

![Smoothing spline estimates of potentially non‐linear relationships between total mortality and the difference between pretest and peak SBP (**A**), peak SBP during exercise (**B**), pretest SBP (**C**) and ratio of peak by pretest SBP (**D**). The solid line depicts the smoothed spline and the shaded area the 95% confidence interval. SBP indicates systolic blood pressure.](JAH3-7-e010735-g004){#jah33648-fig-0004}

Discussion {#jah33648-sec-0020}
==========

In 301 patients with asymptomatic moderate or severe AS, an exaggerated BP response (EBPR) to ETT was seen in 64 (21%) patients. EBPR was more common in patients with higher resting BP values, increased LV mass, and increased systemic arterial stiffness. There was a trend towards a difference in survival across these 3 groups of normal, blunted and exaggerated BP response to exercise.

As expected the most frequent event was AVR, for which symptoms are a class I indication and a blunted BP response is a class IIa indication. However EPBR is not normally recorded and is not a recognized indication for AVR so it is not surprising that it was not prognostically important, although it was identified as potentially harmful response in our logistic regression models. By contrast EBPR has been repeatedly reported in studies on the general population[3](#jah33648-bib-0003){ref-type="ref"}, [4](#jah33648-bib-0004){ref-type="ref"}, [5](#jah33648-bib-0005){ref-type="ref"} as well as in hypertensive patients.[20](#jah33648-bib-0020){ref-type="ref"}, [21](#jah33648-bib-0021){ref-type="ref"}, [22](#jah33648-bib-0022){ref-type="ref"}, [23](#jah33648-bib-0023){ref-type="ref"}, [24](#jah33648-bib-0024){ref-type="ref"}, [25](#jah33648-bib-0025){ref-type="ref"} EBPR depends on age, the resting BP level and exercise intensity, and may also depend on increased sympathetic activity,[20](#jah33648-bib-0020){ref-type="ref"}, [21](#jah33648-bib-0021){ref-type="ref"} endothelial dysfunction and/or large artery stiffness.[22](#jah33648-bib-0022){ref-type="ref"}, [23](#jah33648-bib-0023){ref-type="ref"}, [24](#jah33648-bib-0024){ref-type="ref"}, [25](#jah33648-bib-0025){ref-type="ref"} There is no consensus on its definition. In a cohort of 1999 apparently healthy middle‐aged (40--59 years) Norwegian individuals,[26](#jah33648-bib-0026){ref-type="ref"} EBPR was defined as a systolic BP \>200 mm Hg during a bicycle ergometer exercise test and predicted cardiovascular death and myocardial infarction.[26](#jah33648-bib-0026){ref-type="ref"} However in the Paris Prospective study III cohort of nearly 9000 patients aged 50 to 75 years, a peak systolic BP \>150 mm Hg was used.[27](#jah33648-bib-0027){ref-type="ref"} This cutoff is probably too low since it is only in the resting range of 140 to 159 mm Hg defining the most common form of hypertension.[28](#jah33648-bib-0028){ref-type="ref"} The cutoff of 190 mm Hg we used to define EBPR was reasonable in view of the age of our population and the presence of AS.

Only a few small studies have investigated the hemodynamic responses to ETT in AS,[29](#jah33648-bib-0029){ref-type="ref"}, [30](#jah33648-bib-0030){ref-type="ref"}, [31](#jah33648-bib-0031){ref-type="ref"}, [32](#jah33648-bib-0032){ref-type="ref"} and all focused on revealed symptoms and a reduced BP response.[14](#jah33648-bib-0014){ref-type="ref"} We showed that EBPR was not rare in AS patients. It is likely that the BP response in AS is more complex than the general population and depends on LV contractile reserve and the resistance offered to LV outflow by the stenotic aortic valve. It is possible that the BP response can pseudonormalize because of a fall in stroke volume.[33](#jah33648-bib-0033){ref-type="ref"} Perlman et al showed that a rise in BP after transcutaneous aortic valve replacement (TAVI) was associated with better myocardial contractile reserve even in patients with reduced LV function at baseline.[34](#jah33648-bib-0034){ref-type="ref"} It is possible that a change in the BP response to exercise on serial ETT may reflect the natural history of the LV and valve in AS and provide further prognostic information.

In our patients we found a strong association between EBPR and higher resting BP, more frequent history of hypertension, greater LV mass and also increased systemic arterial stiffness. The LV is therefore exposed to at least 3 types of pressure overloads, 1 from AS per se, another from the concomitant hypertension, and a third from systemic arterial stiffness. In our study, a low systemic arterial distensibility (SVi/PP ≤0.6 mL/m^2^ per mm Hg) was 3‐fold more common in patients with EBPR compared with patients with a normal BP response to exercise. In a univariate logistic regression model, low systemic arterial distensibility was associated with a 2.5‐fold increased risk of EBPR, but in the adjusted model the significant association was not retained. Conversely, higher systemic arterial stiffness was associated with a 3‐fold increased risk of EBPR both in unadjusted and adjusted logistic regression models and was independent of hypertension. Our findings are in line with those demonstrated by the Framingham Heart Study showing that an increased systemic arterial stiffness may accelerate systolic BP elevation during exercise.[35](#jah33648-bib-0035){ref-type="ref"} Thus, the higher prevalence of systemic hypertension and arterial stiffness, as well as AS per se, may lead to abnormal LV geometry, impaired LV function, and worse clinical outcomes.[9](#jah33648-bib-0009){ref-type="ref"}, [10](#jah33648-bib-0010){ref-type="ref"}, [36](#jah33648-bib-0036){ref-type="ref"}

We showed that LV mass was higher in patients with EBPR. Of note, only 3% of patients with EBPR had normal LV geometry compared with 20% in normal and 23% in blunted BP response groups. Similarly, more than a half of patients with EBPR had concentric LV hypertrophy. This suggests that EBPR might aid the decision to start antihypertensive therapy to avoid hypertension mediated target organ damage. Furthermore, the 5 deaths in patients with EBPR occurred relatively early in the first 4 years of follow‐up and all had elevated office and pretest systolic BP. By contrast, deaths occurred more gradually up to 10 years in patients with a normal BP response (Figure [3](#jah33648-fig-0003){ref-type="fig"}). This suggests that patients with high resting BP levels and EBPR were a high‐risk subgroup and might benefit from BP control. There is evidence that angiotensin‐converting enzyme inhibitors may preserve LV function reducing the rate of fibrosis and potentially prolonging the asymptomatic phase.[37](#jah33648-bib-0037){ref-type="ref"}

Limitations {#jah33648-sec-0021}
-----------

There were only 28 deaths in the entire study population, so the power for detecting a prognostic effect of EBPR was low. Further, owing to the retrospective design of the study with a heterogeneous study population it is difficult to exclude the impact of other unmeasured factors which may affect the relationship between EBPR and outcomes. Therefore, this analysis has to be regarded as hypothesis generating but it is strong enough to suggest that further prospective studies are warranted. Serial changes in BP response may also be instructive. Clinic BP before ETT was measured based on a real‐life clinical methodology which might be considered as a limitation for generalizing this in the research context.

Conclusion {#jah33648-sec-0022}
==========

In the EXTAS cohort study of moderate or severe AS, abnormal BP response was highly prevalent. In particular exaggerated BP response at baseline ETT was found in 21% of patients and was strongly related to higher resting BP, LV mass, and increased systemic arterial stiffness independent of hypertension, but could not predict adverse outcomes.
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